Table 1: Patient baseline characteristics.
The clinical and pathologic features of the 32 patients with ovarian granulosa cell tumors and other advanced solid tumors who received STM 434 are summarized. Data are presented as N (%) unless indicated otherwise.
| Baseline Characteristic | All Patients (n=32) |
|---|---|
| Age at screening | |
| Median (range), years | 61 (41–79) |
| <18 | 0 (0) |
| ≥18–65 | 22 (69) |
| ≥65–85 | 10 (31) |
| ≥85 | 0 (0) |
| ECOG Performance Status 0–1 [n (%)] | 32 (100) |
| Prior therapies [median (range)] | 3 (1–11) |
| Sex and child-bearing potential1 [n (%)] | |
| Male | 6 (19) |
| Female | 26 (81) |
| Childbearing potential | 0 (0) |
| Post-menopausal | 10 (38) |
| Surgically sterile | 18 (69) |
| Ethnicity [n (%)] | |
| Hispanic or Latino | 7 (22) |
| Non-Hispanic or Latino | 24 (75) |
| Not reported | 1 (3) |
| Race1 [n (%)] | |
| White | 28 (88) |
| Black/African American | 2 (6) |
| Asian | 1 (3) |
| Not reported | 1 (3) |
| Tumor type [n (%)] | |
| Ovarian granulosa cell | 13 (41) |
| Epithelial ovarian | 7 (22) |
| Colon | 3 (9) |
| Pancreas | 2 (6) |
| Other solid tumor2 | 7 (22) |
1
More than one response can be provided for Race and Childbearing Potential and, as such, the percentage may total more than 100%.
2
Squamous cell carcinoma (2), chondrosarcoma (1), urachal (1), leiomyosarcoma (1), renal cell carcinoma (1), thymic carcinoma (1)